Skip to main content
. Author manuscript; available in PMC: 2024 Dec 1.
Published in final edited form as: Am J Hematol. 2023 Sep 9;98(12):1869–1876. doi: 10.1002/ajh.27084

Figure 2.

Figure 2.

Barriers to allo-HCT in patients for whom it was recommended for but did not subsequently undergo transplant. AML; acute myeloid leukemia. ALL; acute lymphoblastic leukemia (both B-cell ALL and T-cell ALL); MPAL, mixed phenotypic acute leukemia. * It is possible that patients transferred to another center (n = 10 of overall population) may have subsequently received an allo-HCT at an outside institution.